Move to topTop

TOKYO, JAPAN - February 28, 2019 - Terumo Corporation (TSE: 4543) today announced that it will begin selling the Dexcom G4™ PLATINUM Continuous Glucose Monitoring System in Japan. U.S.-based DexCom, Inc., manufactured the product and Terumo has the right to distribute it exclusively in Japan.

The Dexcom G4™ PLATINUM is a medical system for people with diabetes that continuously monitors the glucose level in the interstitial fluid of subcutaneous tissues. Dexcom is a global market leader in real-time CGM, and its products stand out for their high accuracy and a safety mechanism that automatically alerts the user when the level of blood glucose is too low or too high.

Diabetes may lead to: loss of patients' eyesight, kidney disease, myocardial infarction or stroke. Terumo positions the launch of the CGM as an important milestone in contributing to diabetes therapy. The company plans to commence nationwide sales of Dexcom's CGM with Terumo's self-monitoring blood glucose system, and Japan's first tubing-free insulin patch pump. Meanwhile, Terumo will continue to launch Dexcom's next-generation CGM systems as each new model becomes available in Japan.

20190228.jpg

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

 

Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.